METAP1D

Across TCGA pan-cancer cohorts, METAP1D mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated METAP1D data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher METAP1D mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated METAP1D expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where METAP1D mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.800	1.000	.002	22	view →
LUAD	DFS	Tertile	II,III,IV	0.158	1.000	.006	15	view →
PDAC	DFS	Median	All	0.850	0.664	.013	13	view →
LSCC	DFS	Quartile	III,IV	0.411	0.901	.019	10	view →
GBM	OS	Quartile	All	0.895	0.772	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

METAP1D–CCRCC (DFS)

Open the CCRCC breakdown →